Despite CAR-T therapies producing durable and effective responses, access to these treatments remains limited for most patients. Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses strategies to increase the affordability and accessibility of CAR-T therapies. Increasing the number of centers that can administer CAR-T therapies by centralizing the approval process will increase the availability of this therapy to more patients. Dr Gagelmann additionally highlights the need for academic CAR-T cells in developing countries. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.